Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division). The Global Division concentrates its efforts on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established drug names. The Impax Division is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Division is also engaged in the sale and distribution of Zomig (zolmitriptan) products.